本页面由Tiger Trade Technology Pte. Ltd.提供服务

Allogene Therapeutics Inc.

2.04
-0.1300-5.99%
盘后2.040.0015+0.07%19:50 EDT
成交量:502.07万
成交额:1,033.33万
市值:7.04亿
市盈率:-3.13
高:2.18
开:2.17
低:2.03
收:2.17
52周最高:4.46
52周最低:1.04
股本:3.45亿
流通股本:2.67亿
量比:0.93
换手率:1.88%
股息:- -
股息率:- -
每股收益(TTM):-0.6510
每股收益(LYR):-0.8652
净资产收益率:-42.39%
总资产收益率:-22.08%
市净率:1.61
市盈率(LYR):-2.36

数据加载中...

公司资料

公司名字:
Allogene Therapeutics Inc.
交易所:
NASDAQ
成立时间:
2017
员工人数:
151
公司地址:
210 East Grand Avenue,South San Francisco,California,United States
邮编:
94080
电话:
传真:
- -
简介:
Allogene Therapeutics, Inc.于2017年11月30日在特拉华州成立,总部位于加利福尼亚州南旧金山。该公司是一家临床阶段免疫肿瘤学公司,开创了用于治疗癌症的基因工程异体T细胞疗法的开发和商业化。公司正在开发一种现成的T细胞候选产品系列,旨在靶向和杀死癌细胞。Allogene Therapeutics, Inc.工程改造的T细胞是同种异体的,这意味着来自健康供体,用于任何患者,而不是来自患者的个体患者,如自体T细胞的情况。

董事

名称
职位
Zachary Roberts
President and Chief Executive Officer and Director and Chief Medical Officer
Arie Belldegrun
Director and Executive Chair
Deborah Messemer
Independent Director
Elizabeth Barrett
Independent Director
Franz Humer
Lead Independent Director
John DeYoung
Independent Director
Owen Witte
Independent Director
Stephen Mayo
Independent Director
Vicki Sato
Independent Director
Joshua Kazam
Director

股东

名称
职位
Zachary Roberts
President and Chief Executive Officer and Director and Chief Medical Officer
Benjamin Beneski
Senior Vice President and Chief Technical Officer
Earl Douglas
Senior Vice President and General Counsel and Compliance Officer and Corporate Secretary
Geoffrey Parker
Executive Vice President, Chief Financial Officer
Arie Belldegrun
Director and Executive Chair